Inside the FDA's Electronic Revolution: What's Next for Compliance?

Quantity Discounts
1 - 9999
1 - 9999
An opportunity like this rarely comes around — and those that jump on the board can outflank their competitors. Industry advisor Daniel Matlis obtained interviews with five key FDA officials who know where 21 game-changing IT initiatives stand — and how they will affect compliance.

With 21 IT programs under way, the FDA’s “electronic revolution” is imminent. But are you positioned to seize new opportunities — like speeding up label negotiation via real-time online interaction with FDA review staff and reviewing SOPs online with investigators?

Are you prepared for new challenges — like adapting to the powerful new role of the bioinformatics board and aligning your operations with target enterprise architecture?

Clearly, there’s no time to lose in getting up to speed on all 21 IT programs and the FDA’s new mindset.

Here’s where to start ...

From five FDA officials: early warning on “e-compliance”

Now, in this 90-minute Encore presentation, Dan shares these experts’ insights on new FDA e-programs — many of which haven’t been publicly announced yet — goals, tools, standards and expectations.

Sign up your entire team to know what to expect from the FDA’s electronic revolution, including:

  • Key insights and information revealed in the five interviews with FDA officials
  • The goals and responsibilities of the FDA’s bioinformatics board — and how its five business review boards will oversee the e-transformation
  • What the FDA is doing to centralize its IT decisionmaking structure
  • Five objectives driving the FDA’s move to target enterprise architecture
  • How the data standards council is supporting the e-transformation effort by adopting internationally accredited Health Level Seven standards
  • An inside look at 21 e-initiatives, including MedWatch and a nationwide postmarket drug monitoring system
  • New computational tools the agency will use to conduct safety and efficacy analyses
  • Plus, you'll get an opportunity to address your specific concerns during the Q&A session.
This presentation is a must for drug and biologic firm employees responsible for ensuring their document management systems meet the FDA’s expectations for electronic submissions, including:
  • Compliance officers
  • Regulatory and legislative affairs
  • IT professionals
  • Medical affairs
  • Outside consultants
  • General and corporate counsel
  • Quality control
  • Business development officers
  • Science officers
  • Executive management
  • Regulatory/legislative affairs professionals
  • General/corporate counsel
  • QA/QC staff
  • Executive management

Daniel Matlis is the founder and president of Axendia — a consultancy firm that focuses on providing trusted advice to life science executives on business, technology and regulatory issues. Dan’s 18 years of experience in the life sciences industry has included projects in research and development, manufacturing, regulatory compliance, business development and information technology. Prior to founding Axendia, Dan was vice president and general manager at Stelex, a leading consultancy to life science companies. He started his professional career at Ethicon, a Johnson & Johnson company.

Register now!

Date: May 4–22, 2009
Location: Your office or conference room (no need to travel!)
Time: Anytime

Gather your team for maximum benefit! Your investment is for one dial-in.

Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.

Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Registrations may not be cancelled. Please contact customer service to make any substitutions.

Interested in Becoming a Speaker?
We're always looking for industry leaders eager to share their expertise at an FDAnews audioconference, webinar or physical conference. Our seasoned speaker community includes executives in the pharmaceutical, medical device and clinical trial industries, regulatory affairs, quality control, compliance, healthcare and academia, as well as several former — and current — top FDA officials. Click here to complete our speaker opportunity form and have a representative contact you about future opportunities.